Recent News

• 08.11.2026 - IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
• 08.04.2026 - IDEXX Laboratories Announces Second Quarter Results
• 07.28.2026 - IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals
• 07.01.2026 - IDEXX Laboratories to Release 2026 Second Quarter Financial Results
• 05.26.2026 - IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
• 05.19.2026 - IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
• 05.14.2026 - IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
• 05.05.2026 - IDEXX Laboratories Announces First Quarter Results
• 04.08.2026 - IDEXX Laboratories to Release 2026 First Quarter Financial Results
• 02.12.2026 - IDEXX Laboratories to Present at Two Institutional Investor Conferences

Recent Filings

• 08.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2026 - 8-K Current report
• 08.04.2026 - EX-99.1 EX-99.1
• 08.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.01.2026 - SD Specialized disclosure report
• 05.20.2026 - 144 Report of proposed sale of securities
• 05.15.2026 - 8-K Current report
• 05.14.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.14.2026 - 4 Statement of changes in beneficial ownership of securities